← FDA Drug Approvals (Drugs@FDA)

EDARAVONE

ANDA · Abbreviated New Drug Application (Generic) · Sponsor: PHARMOBEDIENT · Approved 2024-10-31

Drug application

FDA Application #

ANDA217565

Application type

Abbreviated New Drug Application (Generic)

Brand name

EDARAVONE

Generic name

EDARAVONE

Active ingredients

EDARAVONE

Dosage form

SOLUTION

Route

INTRAVENOUS

Marketing status

Prescription

Sponsor

PHARMOBEDIENT

Manufacturer

XGen Pharmaceuticals DJB, Inc.

First approval

2024-10-31

Source

Authoritative

Drugs@FDA application overview

Machine

JSON-LD · Markdown